Sensei Biotherapeutics, Inc. (SNSE)
NASDAQ: SNSE · IEX Real-Time Price · USD
0.790
-0.670 (-45.89%)
At close: May 24, 2024, 4:00 PM
0.775
-0.015 (-1.85%)
After-hours: May 24, 2024, 7:58 PM EDT

Company Description

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients.

The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.

It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors.

The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28.

It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program.

The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Sensei Biotherapeutics, Inc.
Sensei Biotherapeutics logo
Country United States
Founded 2005
IPO Date Feb 4, 2021
Industry Biotechnology
Sector Healthcare
Employees 28
CEO John K. Celebi M.B.A.

Contact Details

Address:
1405 Research Blvd, Suite 125
Rockville, Maryland 20850
United States
Phone (240) 243-8000
Website senseibio.com

Stock Details

Ticker Symbol SNSE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $19.00
CIK Code 0001829802
CUSIP Number 81728A108
ISIN Number US81728A1088
SIC Code 2834

Key Executives

Name Position
John K. Celebi M.B.A. President, Chief Executive Officer and Director
Dr. Edward Van der Horst Ph.D. Chief Scientific Officer
Lora Pike Vice President of Investor Relations and Communications
Christopher W. Gerry J.D. Senior Vice President, General Counsel and Secretary
Stephanie Krebs M.B.A., M.S. Chief Business Officer
Dr. Aaron Weitzman FACP, M.D., Ph.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
May 23, 2024 8-K Current Report
May 9, 2024 10-Q Quarterly Report
May 9, 2024 8-K Current Report
Apr 29, 2024 ARS Filing
Apr 29, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2024 DEF 14A Other definitive proxy statements
Apr 12, 2024 8-K Current Report
Apr 2, 2024 8-K Current Report
Mar 7, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Mar 5, 2024 8-K Current Report